Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Abstract

OBJECTIVE This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses. RESEARCH DESIGN AND METHODS A triple-blind, placebo-controlled, 30-week study at 82 U.S. sites was performed with 336 randomized… (More)

Topics

7 Figures and Tables

Cite this paper

@article{DeFronzo2005EffectsOE, title={Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.}, author={Ralph A DeFronzo and Robert E. Ratner and Jenny Han and Dennis Dong Hwan Kim and Mark S Fineman and Alain D. Baron}, journal={Diabetes care}, year={2005}, volume={28 5}, pages={1092-100} }